Advisor Partners II’s Nektar Therapeutics NKTR Stock Holding History

Advisor Partners II’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-681	Closed	-$23.1K	–	1030
2022 Q4	$23.1K	Buy	+681	New	+$33K	﹤0.01%	934

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Advisor Partners II's NKTR Position: Q1 2023 in Review

Advisor Partners II sold out of Nektar Therapeutics (NKTR) in Q1 2023, closing a stake of 681 shares — an estimated $23.1K sold.

Advisor Partners II first reported a position in NKTR in Q4 2022 and held it in 1 quarter. The position peaked at $23.1K in Q4 2022. 194 funds tracked by Wall St. Rank hold NKTR as of Q1 2023.

Advisor Partners II reported no remaining Nektar Therapeutics position as of Q1 2023 after selling out during the quarter.
Advisor Partners II sold 681 Nektar Therapeutics shares in Q1 2023, an estimated $23.1K.
Advisor Partners II first reported a position in Nektar Therapeutics in Q4 2022 and held it in 1 quarter.
Advisor Partners II's Nektar Therapeutics position peaked at $23.1K in Q4 2022.
194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2023.

Based on Advisor Partners II's 13F filing for Q1 2023, filed 15 May 2023.